BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 16/02/2016

Completeness Assessments for Type II Active Pharmaceutical Ingredient Drug Master Files Under the Generic Drug User Fee Amendments of 2012; Guidance for Industry; Availability

The Food and Drug Administration (FDA or Agency) is announcing the availability of a guidance for industry entitled "Completeness Assessments for Type II API DMFs Under GDUFA". It finalizes the draft guidance entitled "Initial Completeness Assessments for Type II API DMFs Under GDUFA", which published on October 2, 2012. This guidance is intended for holders of Type II active pharmaceutical ingredient (API) drug master files (DMFs) that are or will be referenced in an abbreviated new drug application (ANDA), an amendment to an ANDA, a prior approval supplement (PAS) to an ANDA, or an amendment to a PAS (generic drug submissions).

Source: Federal Register — Food and Drug AdministrationOpen original release →